Chronic hepatitis C in the Czech Republic: Forecasting the disease burden
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články
PubMed
31241282
DOI
10.21101/cejph.a5350
Knihovny.cz E-zdroje
- Klíčová slova
- Czech Republic, disease burden, epidemiology, hepatitis C,
- MeSH
- antivirové látky ekonomika terapeutické užití MeSH
- chronická hepatitida C farmakoterapie ekonomika epidemiologie MeSH
- dospělí MeSH
- hepatocelulární karcinom epidemiologie MeSH
- jaterní cirhóza epidemiologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- nádory jater epidemiologie MeSH
- osobní újma zaviněná nemocí * MeSH
- prevalence MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- surveillance populace MeSH
- transplantace jater MeSH
- věkové rozložení MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Česká republika MeSH
- Názvy látek
- antivirové látky MeSH
OBJECTIVE: Chronic HCV infection is associated with cirrhosis of the liver, hepatocellular carcinoma (HCC), and liver transplantation. HCV disease burden and the impact of new potent direct acting antivirals (DAAs) in the Czech Republic are unknown. METHODS: Using a modelling framework, HCV disease progression in the Czech Republic was predicted to 2030 under the current standard of care treatment structure. In addition, two strategies to reduce the future burden of HCV infection were modelled: an incremental increase in treatment annually and WHO targets. RESULTS: The number of viremic infected individuals in the Czech Republic is estimated to peak in 2026 (n = 55,130) and to decline by 0.5% by 2030 (n = 54,840). The number of individuals with compensated cirrhosis (n = 1,400), decompensated cirrhosis (n = 80), HCC (n = 70), and liver-related deaths (n = 60) is estimated to more than double by 2030. Through aggressive increases in diagnosis and treatment, HCV related mortality may decrease by 70% by 2030. CONCLUSIONS: Disease burden associated with chronic HCV infection is projected to peak in the Czech Republic in 30-40 years. Assuming that the current portion of DAAs used remains constant, a significant reduction in HCV disease burden is possible through increased diagnosis and treatment through 2030. This analysis provides evidence in order to facilitate the development of national strategies for HCV care and management in the Czech Republic.
Center for Disease Analysis Lafayette Colorado USA
Clinic of Infectious Diseases University Hospital Brno Masaryk University Brno Czech Republic
Citace poskytuje Crossref.org
HCV Elimination in Central Europe with Particular Emphasis on Microelimination in Prisons
Therapy of chronic hepatitis C in people who inject drugs: focus on adherence
How close are we to hepatitis C virus elimination in Central Europe?
